<DOC>
	<DOCNO>NCT00083993</DOCNO>
	<brief_summary>In clinical research study , postmenopausal subject metastatic breast cancer give either combination temsirolimus ( CCI-779 ) letrozole placebo letrozole first-line hormonal treatment . The primary endpoint study determine overall progression free survival . Individual subject participate active treatment phase study disease progression withdrawal consent , provide test article tolerate . All subject ask participate long-term follow-up phase study , include follow-up every 3 month disease progression ( subject withdraw reason document progressive disease ) new cancer treatment receive , survival . The estimate duration study participation 34 month .</brief_summary>
	<brief_title>Study Evaluating CCI-779 Letrozole Post-menopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Women age great 18 year . Postmenopausal subject Confirmed diagnosis locally advance ( amenable curative surgery and/or radiation ) metastatic breast cancer ( Stage 3B 4 respectively , American Joint Committee Cancer Criteria ) Extensive visceral disease Subjects bone site disease Prior radiation therapy site measurable disease subject solitary measurable lesion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>